US Patent Issued to Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, President and Fellows of Harvard College on March 25 for "Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies" (Massachusetts Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,409, issued on March 25, was assigned to Dana-Farber Cancer Institute Inc. (Boston), Beth Israel Deaconess Medical Center (Boston) and President and Fellows of Harvard College (Cambridge, Mass.).

"Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies" was invented by Gordon J. Freeman (Brookline, Mass.), Vassiliki A. Boussiotis (Brookline, Mass.), Xia Bu (Brookline, Mass.), Vikram R. Juneja (Boston), Arlene H. Sharpe (Brookline, Mass.), Nikolaos Patsoukis (Boston), Jessica Weaver (Brighton, Mass.) and Laura Strauss (Boston).

According to the abstract* released by the U.S. ...